Ashton Thomas Securities, LLC Intra Cellular Therapies, Inc. Transaction History
Ashton Thomas Securities, LLC
- $515 Billion
- Q3 2024
A detailed history of Ashton Thomas Securities, LLC transactions in Intra Cellular Therapies, Inc. stock. As of the latest transaction made, Ashton Thomas Securities, LLC holds 172 shares of ITCI stock, worth $14,792. This represents 0.0% of its overall portfolio holdings.
Number of Shares
172Holding current value
$14,792% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ITCI
# of Institutions
377Shares Held
84.1MCall Options Held
319KPut Options Held
143K-
Vanguard Group Inc Valley Forge, PA9.63MShares$828 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.32MShares$544 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY5.29MShares$455 Million0.03% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT3.85MShares$331 Million1.4% of portfolio
-
Avoro Capital Advisors LLC New York, NY3.05MShares$262 Million3.36% of portfolio
About Intra-Cellular Therapies, Inc.
- Ticker ITCI
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 94,401,696
- Market Cap $8.12B
- Description
- Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. The company offers CAPLYTA for the treatment of schizophrenia in adults. It is also involved in dev...